epiH Search

CLOSE



Epidemiol Health > Accepted Articles
Epidemiology and Health 2021;e2021097.
DOI: https://doi.org/10.4178/epih.e2021097    [Accepted] Published online Nov 9, 2021.
Real-world incidence of endophthalmitis after intravitreal anti-VEGF injection: Common Data Model in ophthalmology
Yongseok Mun1  , Seng Chan You2  , Da Yun Lee1  , Seok Kim3  , Yoo-Ri Chung4  , Kihwang Lee4  , Ji Hun Song4  , Young Gun Park5  , Young Hoon Park5  , Young-Jung Roh6  , Se Joon Woo1  , Kyu Hyung Park1  , Rae Woong Park2  , Sooyoung Yoo3  , Dong Jin Chang6  , Sang Jun Park1 
1Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea
2Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea
3Healthcare ICT Research Center, Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam, Korea
4Department of Ophthalmology, Ajou University School of Medicine, Suwon, Korea
5Department of Ophthalmology and Visual Science, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
6Department of Ophthalmology and Visual Science, Yeouido St. Mary’s Hospital, College of Medicine, Seoul, Korea
Correspondence  Sang Jun Park ,Tel: +82-31-787-7382, Email: sangjunpark@snu.ac.kr
Received: Aug 19, 2021  Accepted after revision: Nov 9, 2021
Abstract
Objectives:
To evaluate the real-world incidence of endophthalmitis after intravitreal anti-vascular endothelial growth factor (VEGF) injection through the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM).
Method:
Patients with endophthalmitis developing within 6 weeks after intravitreal anti-VEGF injections were identified in three large OMOP CDM databases.
Results:
We identified 23,490 patients who received 128,123 intravitreal anti-VEGF injections. The incidence rates of endophthalmitis were 15.75 per 10,000 patients and 2.97 per 10,000 injections. The incidence rates of endophthalmitis for bevacizumab, ranibizumab, and aflibercept (per 10,000 injections) were 3.65, 1.39, and 0.76, respectively. The annual incidences have been below 5.00 per 10,000 injections since 2011 although the number of intravitreal anti-VEGF injections have been increasing. Bevacizumab presented a higher incidence rate for endophthalmitis than ranibizumab and aflibercept (incidence rate ratio = 3.17; P value = 0.021).
Conclusions:
The incidence of endophthalmitis after intravitreal anti-VEGF injections have been stabilized since 2011 despite the explosive increase of anti-VEGF injections. The off-label use of bevacizumab raised more endophthalmitis significantly. The OMOP CDM, which includes off-label uses, laboratory data, and scalable standardized database, could provide a novel strategy to reveal real-world evidence especially in ophthalmic fields.
Keywords: Anti-VEGF; Endophthalmitis; CDM; Real-world; Evidence
TOOLS
Share :
METRICS Graph View
  • 0 Crossref
  • 0 Scopus
  • 497 View
  • 52 Download


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
FOR AUTHORS AND REVIEWERS
Editorial Office
Department of Preventive Medicine, Yonsei University College of Medicine
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
TEL: +82-2-745-0662   FAX: +82-2-764-8328    E-mail: office.epih@gmail.com

Copyright © 2021 by Korean Society of Epidemiology.

Developed in M2PI

Close layer
prev next